Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy MacroGenics stock
Learn how to easily invest in MacroGenics stock.
MacroGenics Inc is a biotechnology business based in the US. MacroGenics shares (MGNX) are listed on the NASDAQ and all prices are listed in US Dollars. MacroGenics employs 427 staff and has a trailing 12-month revenue of around $66.9 million.
How to buy shares in MacroGenics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – MGNX – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
MacroGenics stock price (NASDAQ: MGNX)Use our graph to track the performance of MGNX stocks over time.
MacroGenics shares at a glance
|Latest market close||$3.04|
|52-week range||$2.13 - $22.78|
|50-day moving average||$3.97|
|200-day moving average||$7.95|
|Wall St. target price||$10.72|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-3.56|
Buy MacroGenics shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy MacroGenics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
MacroGenics price performance over time
|1 week (2022-09-16)||-11.88%|
|1 month (2022-08-25)||-22.45%|
|3 months (2022-06-24)||-8.98%|
|6 months (2022-03-24)||-66.88%|
|1 year (2021-09-24)||-84.60%|
|2 years (2020-09-25)||-87.85%|
|3 years (2019-09-25)||12.97|
|5 years (2017-09-22)||17.05|
Is MacroGenics stock undervalued or overvalued?
Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MacroGenics's PEG ratio
MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$66.9 million|
|Gross profit TTM||$-139,781,000|
|Return on assets TTM||-42.64%|
|Return on equity TTM||-94.75%|
|Market capitalisation||$212 million|
TTM: trailing 12 months
MacroGenics share dividends
We're not expecting MacroGenics to pay a dividend over the next 12 months.
MacroGenics share price volatility
Over the last 12 months, MacroGenics's shares have ranged in value from as little as $2.13 up to $22.78. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 1.9365. This would suggest that MacroGenics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MacroGenics, Inc. , a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc.
MacroGenics in the news
Why MacroGenics Stock Sank Today
MacroGenics to Participate in Upcoming Investor Conferences
MacroGenics to Participate in Upcoming Investor Conferences
Frequently asked questionsWhat percentage of MacroGenics is owned by insiders or institutions?
Currently 2.598% of MacroGenics shares are held by insiders and 104.011% by institutions. How many people work for MacroGenics?
Latest data suggests 427 work at MacroGenics. When does the fiscal year end for MacroGenics?
MacroGenics's fiscal year ends in December. Where is MacroGenics based?
MacroGenics's address is: 9704 Medical Center Drive, Rockville, MD, United States, 20850 What is MacroGenics's ISIN number?
MacroGenics's international securities identification number is: US5560991094 What is MacroGenics's CUSIP number?
MacroGenics's Committee on Uniform Securities Identification Procedures number is: 556099109
More guides on Finder
How to buy YanGuFang International Group (YGF) stock when it goes public
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
What are the FAANG stocks and how do you invest in them?
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
How to buy soccer stocks
A simple guide to buying stocks in your favorite European soccer team.
How to buy Juventus stock
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
How to buy AS Roma stock
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
How to buy Borussia Dortmund stock
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
How to buy Lead Real Estate Co. (LRE) stock when it goes public
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
How to buy Third Harmonic Bio (THRD) stock
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
How to buy LINKBANCORP (LNKB) stock
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
Ask an Expert